title: Evaluation of TcpF-A2-CTB chimera and evidence of additive protective efficacy of immunizing with TcpF and CTB in the suckling mouse model of cholera.
abstract: The secreted colonization factor, TcpF, which is produced by Vibrio cholerae 01 and 0139, has generated interest as a potential protective antigen in the development of a subunit vaccine against cholera. This study evaluated immunogenicity/protective efficacy of a TcpF holotoxin-like chimera (TcpF-A2-CTB) following intraperitoneal immunization compared to TcpF alone, a TcpF+CTB mixture, or CTB alone. Immunization with the TcpF-A2-CTB chimera elicited significantly greater amounts of anti-TcpF IgG than immunization with the other antigens (P<0.05). Protective efficacy was measured using 6-day-old pups reared from immunized dams and orogastrically challenged with a lethal dose of El Tor V. cholerae 01 Inaba strain N16961. Protection from death, and weight loss analysis at 24 and 48 hours post-infection demonstrated that immunization with TcpF alone was poorly protective. However, immunization with TcpF+CTB was highly protective and showed a trend toward greater protection than immunization with CTB alone (82% vs 64% survival). Immunization with the TcpF-A2-CTB chimera demonstrated less protection (50% survival) than immunization with the TcpF+CTB mixture. The TcpF-A2-CTB chimera used for this study contained the heterologous classical CTB variant whereas the El Tor CTB variant (expressed by the challenge strain) was used in the other immunization groups. For all immunization groups that received CTB, quantitative ELISA data demonstrated that the amounts of serum IgG directed against the homologous immunizing CTB antigen was statistically greater than the amount to the heterologous CTB antigen (P≤0.003). This finding provides a likely explanation for the poorer protection observed following immunization with the TcpF-A2-CTB chimera and the relatively high level of protection seen after immunization with homologous CTB alone. Though immunization with TcpF alone provided no protection, the additive protective effect when TcpF was combined with CTB demonstrates its possible value as a component of a multivalent subunit vaccine against Vibrio cholerae 01 and 0139.
authors.affiliation: Department of Microbiology, University of Colorado School of Medicine, Aurora, Colorado, United States of America.
authors.forename: Gregory A
authors.initials: GA
authors.lastname: Price
authors.forename: Randall K
authors.initials: RK
authors.lastname: Holmes
mesh_terms: D000818:Animals; D000831:Animals, Newborn; D000833:Animals, Suckling; D000907:Antibodies, Bacterial / Q000276:immunology; D000917:Antibody Formation / Q000276:immunology; D000918:Antibody Specificity / Q000276:immunology; D001426:Bacterial Proteins / Q000008:administration & dosage / Q000276:immunology*; D002771:Cholera / Q000097:blood / Q000276:immunology* / Q000382:microbiology / Q000517:prevention & control*; D002772:Cholera Toxin / Q000008:administration & dosage / Q000235:genetics / Q000276:immunology*; D004195:Disease Models, Animal; D004591:Electrophoresis, Polyacrylamide Gel; D004797:Enzyme-Linked Immunosorbent Assay; D005243:Feces / Q000382:microbiology; D005838:Genotype; D007114:Immunization; D007070:Immunoglobulin A / Q000097:blood / Q000276:immunology; D007274:Injections, Intraperitoneal; D051379:Mice; D011401:Promoter Regions, Genetic / Q000235:genetics; D011993:Recombinant Fusion Proteins / Q000276:immunology*; D014157:Transcription Factors / Q000008:administration & dosage / Q000276:immunology*; D016896:Treatment Outcome; D014734:Vibrio cholerae / Q000235:genetics / Q000276:immunology; D015431:Weight Loss
chemical_list: D000907:Antibodies, Bacterial; D001426:Bacterial Proteins; D007070:Immunoglobulin A; D011993:Recombinant Fusion Proteins; D014157:Transcription Factors; C075626:tcpN protein, Vibrio cholerae; D002772:Cholera Toxin